Heidi J. Crayton, MD, is an assistant professor and MS specialist in the Department of Neurology-Multiple Sclerosis (MS) Center at Georgetown University Hospital in Washington, DC.
Dr. Crayton received her medical degree from the Medical College of Pennsylvania in Philadelphia, where she also completed an internal medicine internship. Subsequently, she completed an adult neurology residency and an MS fellowship at Georgetown University Hospital. She is a member of the American Academy of Neurology and the Consortium of MS Centers. In addition, she is a member of the Professional Advisory Committee of the National Capitol Chapter of the National MS Society. Dr. Crayton has been a principal and co-principal investigator for several studies on MS treatments. She has published articles on topics such as treatment for inflammatory arthritis and managing the symptoms of MS, in addition to participating development of a treatment algorithm for MS.

Thomas Scott, M.D., has been at Allegheny General Hospital in Pittsburgh, for the last sixteen years and is now a Professor of Neurology, Drexel University College of Medicine, and directs the Neurology Residency training. He is the Director of the Allegheny Multiple Sclerosis Treatment Center. Studies of immunology and epidemiology of multiple sclerosis and multicenter drug studies of multiple sclerosis treatments began at the center in the early 1990s and have gradually expanded through the years. He is also a member of the Consortium of MS Treatment Centers, and the advisory board of the Allegheny Chapter of the National Multiple Sclerosis Society. He is a frequent reviewer for Neurology and as well as several other peer review journals. He has written several book chapters and has over 40 published articles in the field of neurology, mostly concerning multiple sclerosis and other inflammatory illnesses. Dr. Scott was a principal investigator in many MS multicenter drug trials including: CHAMPS, PROMISE, CORAL, ACT, the Phase III natalizumab trial, AIMS, Double Dose Copaxone®, CHAMPIONS, among others.

Andrew R. Pachner, MD is a Professor at the Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey (UMDNJ) Medical School. He is also an Attending Physician at Georgetown University Hospital in Washington, DC, and UMDNJ-NJMS Hospital in Newark, NJ.

Dr. Pachner has served as Vice-Chairman for the Department of Neurology at Georgetown University School of Medicine, Acting Chairman for the Department of Neurosciences, UMDNJ-New Jersey Medical School, and Co-director of the Neurological Institute of New Jersey. He is a member of the American Academy of Neurology, American Neurological Association, American Association of Immunology, American Society of Microbiology and the National Multiple Sclerosis Society. Dr. Pachner has also served as Principal Investigator for many industry and government-sponsored clinical trials related to antibodies in multiple sclerosis treatment, authored numerous scientific articles and lectured at universities, government organizations, hospitals and national medical conferences.

Joseph R. Lacy, MD is the head of the Department of Neurology at the Palo Alto Medical Foundation and an Adjunct Clinical Associate Professor of Neurology at Stanford University in Palo Alto, California. Dr. Lacy is Co- Director of the MS Clinic at the Palo Alto Medical Foundation, and is Chairman of the Silicon Valley Chapter of the National Multiple Sclerosis Society. He is board certified in Neurology and in Electrodiagnostic Medicine. Dr. Lacy received his medical degree from the College of Medicine at the University of Vermont, completed a medical internship at Boston University Medical Center in Boston, Massachusetts, and a medical residency at the University of California. He undertook his neurology residency at the University of Pennsylvania in Philadelphia, Pennsylvania, and a neurology fellowship at the National Institutes of Health in Bethesda, Maryland. Dr. Lacy was formerly a member of the academic faculty in the Department of Neurology at the University of Colorado, Denver, Colorado before coming to the Palo Alto Medical Foundation.

Copaxone (Glatiramer Acetate) is a registered trademark of Teva Pharmaceutical Industries, Ltd.

1-22108-01